Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
Status and phase
Completed
Phase 2
Conditions
Rubella
Varicella
Mumps
Measles
Treatments
Biological: measles, mumps, and rubella virus vaccine live
Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
Details and patient eligibility
About
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.
Full description
The duration of treatment is 6 weeks.
Enrollment
1,210 patients
Sex
All
Ages
12 to 18 months old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Healthy children 12 to 18 months of age
Exclusion criteria
- History or prior exposure to measles, mumps, or rubella
- History of allergic reactions to any component of the vaccines as evaluated by the study doctor
Trial design
Primary purpose
Prevention
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Double Blind
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems